Single-Center, Phase 2, Open-Label Trial Evaluating the Efficacy and Safety of Obinutuzumab in Treatment of Immunosuppression-Resistant Primary FSGS, or Contraindication to High-Dose Corticosteroids

Authors: Ladan Zand, Eddie L. Greene, Wisit Cheungpasitporn, Maria Jose Vargas-Brochero, Miriam Machado, Sanjeev Sethi, Pierre M. Ronco, Fernando C. Fervenza

Published: 2024-10-28

DOI: 10.1681/asn.2024yfph3q3v

Keywords: No keywords found.

Abstract:
No abstract found.

Source: